Results 201 to 210 of about 231,542 (282)

MEK inhibitor CS3006 [PDF]

, 2020
openaire   +1 more source

TANC1::HTRA1 fusion in schwannomas

Brain Pathology, EarlyView.
Ilay Caliskan, Kanish Mirchia, Walter Patrick Devine, Melike Pekmezci   +3 more
wiley   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

Melanoma: Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Fu Y, Liu J, Mo Z, Wang B, Deng Y, Jiang Y.   +5 more
europepmc   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Un-sweetening the deal: targeting glucose metabolism in brain arteriovenous malformations. [PDF]

EMBO Mol Med
Rudnicki M, Haas TL.
europepmc   +1 more source

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

cGAS-STING Pathway-Induced BST2 Enhances HPV-Infected Keratinocyte Proliferation in Condyloma Acuminata. [PDF]

Biomedicines
Huang H, Liu L, Xie X, Cao Y, Gu Z.
europepmc   +1 more source

Growth differentiation factor 15 mitigates lipotoxic steatosis by preserving mitochondrial morphodynamics and augmenting fatty acid oxidation in hepatocytes and liver organoids

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Growth differentiation factor 15 (GDF15) has emerged as a promising metabolic regulator with hepatoprotective properties in metabolic dysfunction‐associated steatotic liver disease (MASLD), yet its underlying mechanisms remain elusive.
Jia Li, Qi Zhou, Mengmeng Xia, Yakun Li, Junyu Wang, Manon Buist‐Homan, Vincent E. de Meijer, Hans Blokzijl, Klaas Nico Faber, Han Moshage   +9 more
wiley   +1 more source

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS^Q61R Human Endothelial Cells. [PDF]

Pediatr Blood Cancer
Alharbi S, Wagner A, Merkle S, Pastura P, McDaniel CG, Fox D, Xu Y, Cras TDL.   +7 more
europepmc   +1 more source